It has to be said that cancer patients in China have caught up with an unprecedented good era! Four years ago, when the first PD-1 keytruda was listed in China, the annual cost reached 300000 yuan. Most domestic families can't afford it, so they can only look at the medicine and sigh.
The good news is that in recent years, the research and development of antitumor drugs in China has developed rapidly, and the independently developed immunotherapeutic drugs have risen rapidly. In just four years since the first domestic PD-1 treprizumab was listed in 2018, we have ushered in the seventh domestic pd-1-sullivan!
Good news! The first domestic "Pan cancer species" PD-1 -- sloulimab is on the market!
On March 24, 2022, we received great good news. The innovative PD-1 drug serplulimab (hlx10) independently developed in China was approved for monotherapy of unresectable and metastatic highly microsatellite unstable (MSI-H) solid tumors after standard treatment failure. It is the seventh approved PD-1 monoclonal antibody in China and the first domestic "Pan cancer species" PD-1, It has fully opened a new era of unlimited cancer treatment in China.
This approval is based on the key phase II clinical study (code named astrum010). A total of 108 patients were enrolled and achieved great success.
The results show that:
The objective response rate (ORR) of colorectal cancer subgroup was as high as 46.7%;
The 12-month survival (OS) rate of 58 patients with sensitivity and efficacy analysis was 82.4%, and the disease control time was long.
Domestic experts believe that such efficacy is completely comparable to PD-1 at home and abroad.
It is necessary to remind patients that at present, the listing of srulizumab is approved with conditions. According to the requirements of the State Food and drug administration, further research is needed after the drug is listed to further confirm its effectiveness and safety in the treatment of adult patients with unresectable or metastatic MSI-H advanced solid tumors.
In addition, the trials of Sullivan in other multiple tumors, such as non-small cell lung cancer, liver cancer, head and neck tumors, are in full swing.
Neoadjuvant or adjuvant therapy for gastric cancer
Histologically confirmed, untreated gastric cancer or gastroesophageal junction cancer, and histological examination was adenocarcinoma. (neoadjuvant or adjuvant treatment of gastric cancer with rituximab combined with chemotherapy)
First line treatment of lung cancer
Histologically confirmed stage Ⅲ B, Ⅲ C or Ⅳ non squamous non-small cell lung cancer that cannot be operated or radiotherapy has not received systematic treatment in the past. (first line treatment of metastatic non squamous non-small cell lung cancer with Sullivan combined with chemotherapy)
13 PD-1 / L1 models are listed in China, and the major market points of drug use and medical insurance information
In the past decade, from initial efficacy to successful listing, PD-1 / PD-L1 immunotherapy is one of the most successful tumor immunotherapy, which has successfully set off a revolution in tumor treatment and led the reform of cancer treatment! Immune checkpoint inhibitor aims to make full use of the human body's own immune system to resist and fight cancer. It can kill cancer cells by blocking PD-1 / PD-L1 signal pathway. It has the potential to treat various types of tumors, substantially improve the survival time of patients with advanced tumors, and become a "specific" drug for patients with tumors.
In the past two years, with the listing of more domestic PD-1 drugs and the inclination of medical insurance and assistance policies, the price has fallen below 1000 yuan. For example, the price of 80 mg treprizumab is only 906.08 yuan, breaking the lowest record of PD-1! It also makes PD-1 inhibitor, which was originally a "divine medicine", really become a treatment option within the reach of patients! Even the U.S. FDA calls out: Chinese pharmaceutical companies are welcome to bring low-cost PD-1 / PD-L1 to the United States.
So far, 13 immune checkpoint inhibitors have been listed in China, including 7 domestic PD-1, 1 domestic PD-L1, 2 imported PD-1 and 2 imported PD-L1. The Department of medicine of cancer free home has made a detailed inventory of the medication information of these 13 PD-1 / L1 medical insurance products currently on the market in China. Click it to view the large picture, and the patients can collect it for standby)
blossom everywhere! Many new immunotherapies have opened the door to the long-term survival of cancer patients. In the past decade, cancer immunotherapy has made great progress and reversed the survival of advanced patients. In addition to CTLA-4, PD-1 / L1, LAG-3 and other immune checkpoint inhibitors, many new drugs are under development all over the world, such as tigit inhibitors, Tim-3 inhibitors and so on.
Source: cn-healthcare
https://www.cn-healthcare.com/articlewm/20220329/content-1331933.html
